[DDB BOARD REGULATION NO. 8, S. 2007, December 11, 2007]

AMENDING BOARD REGULATION NO. 2, SERIES OF 2003, ENTITLED 'IMPLEMENTING RULES AND REGULATIONS GOVERNING ACCREDITATION OF DRUG TESTING LABORATORIES IN THE PHILIPPINES"

WHEREAS, Section 39 of Republic Act 9165, also known as the "Comprehensive Dangerous Drugs Act of 2002", mandates the Department of Health (DOH) to "license and accredit drug testing centers in each province and city in order to assure their capacity, competence, integrity and stability to conduct the laboratory examinations and tests";

WHEREAS, the Dangerous Drugs Board (DDB) promulgated Board Regulation No. 2, Series of 2003, providing forthe Implementing Rules and Regulations Governing Accreditation of Drug Testing Laboratories in the Philippines;

WHEREAS, the Drug Testing Operations Management and Information Systems (DTOMiS) was adopted by the DOH and approved by the DDB to gather data on the drug tjng laboratories (DTLs) nationwide and monitor and regulate them; the DTOMIS was originally designed as an interim information technology olution, utilizing the existing hardware infrastructure of the DOH to address the need for a vstem to manage drug testing activities for several government agency end-beneficiaries;

WHEREAS, the National Computer Center (NCC) endorsed and released funding for the continuing upgrade of the hardware and software infrastructure development for the DTOMIS;

WHEREAS, there is a need to utilize new technologies recently made available in the Philippines to preserve the integrity and quality of laboratory examinations;

WHEREFORE, be it RESOLVED, as it is hereby RESOLVED, to amend the Dangerous Drugs Board (DDB) Regulation No. 2, Series of 2003, as hereunder provided:

SECTION 1. Section 3 (Definition of Terms) of DDB Regulation No. 2, Series of 2003, is hereby amended by inserting the definition of the word "Board" between the definition of the phrase "Applications Service Provider" and the definition of the word "Bureau", as follows:

> "Board refers to the Dangerous Drugs Board created under Section 77, Article IXofRA9165."

SECTION 2. Section 6, Sub-Paragraph 5.1 (Information Technology Requirements) of DDB Regulation No. 2, Series of 2003, is hereby amended, such that the

provision shall now read as follows:

> "5.1 The laboratory shall maintain a set of information technology (IT) equipment whose specification shall conform to the minimum requirement set by the DOH as the need arises and after due consultation with the stakeholders. New IT equipment requirements shall be disseminated through a DOH memorandum circular which shall be posted in the DOH website,"

SECTION 3. Section 6, Sub-Paragraph 5.2 (Information Technology Requirements) of DDB Regulation No. 2, Series of 2003, is hereby amended, such that the provision shall now read as follows:

> "5.2 The laboratory shall have access to and utilize the Integrated Drug Testing Operations Management Information System (IDTOMIS), which is the Application Service Provider (ASP) approved and maintained by the DOH."

SECTION 4. Section 6 (Information Technology Requirements) of DDB Regulation No. 2, Series of 2003, is hereby amended by adding Sub-Paragraph 5.3, which reads as follows:

> "5.3 Collected subscription fees for the IT Provider shall be used as follows:
>
> "5.3.1 Two-thirds (2/3) or 66.67% of the collected fees shall be used to maintain the IDTOMIS and shoulder confirmatory test requests of screening drug testing laboratories subject to the guidelines approved by the Board and the DOH; and
>
> "5.3.2 One-third (1/3) or 33.33% of the collected fees shall be used to fund drug abuse prevention and control programs, projects and activities of the Board, subject to the guidelines approved by the Board."

SECTION 5, Section 6, Paragraph 14 (Urine Specimen Collection: Handling and Disposal) of DDB Regulation No. 2, Series of 2003, is hereby amended, such that the entire paragraph shall now read as follows:

> "14. Urine Specimen Collection: Handling and Disposal
>
> "The laboratory shall follow the DOH-prescribed guidelines in the collection, handling and disposal of urine specimens. Universal precaution shall be observed at all times.
>
> "14.1 Clients and analysts shall be required to submit fingerprints for every drug testing transaction following the IDTOMIS Manual as adopted by the Board.
>
> "14.2 Laboratories shall use waterless urinals to prevent dilution and tampering of specimen.
>
> "14.3 Confirmatory laboratories shall comply with the procedures prescribed in the Quality Manual for Confirmatory Drug Testing Laboratories as adopted by the Board."